Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.

[1]  G. Watts,et al.  Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. , 2017, Journal of clinical lipidology.

[2]  D. Pennell,et al.  Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial , 2017, European heart journal.

[3]  L. Hemphill,et al.  Lipoprotein(a): A Lipoprotein Whose Time Has Come , 2017, Current Treatment Options in Cardiovascular Medicine.

[4]  V. Salomaa,et al.  Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium , 2017, European heart journal.

[5]  G. Watts,et al.  Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. , 2017, The lancet. Diabetes & endocrinology.

[6]  P. Grützmacher,et al.  The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on , 2017, Clinical Research in Cardiology Supplements.

[7]  A. Sahebkar,et al.  Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials , 2017, BMC Medicine.

[8]  D. Wellsted,et al.  Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention , 2015, Thrombosis and Haemostasis.

[9]  F. Raal,et al.  Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease , 2016, Cardiovascular Drugs and Therapy.

[10]  J. Witztum,et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.

[11]  D. Pennell,et al.  High prevalence of raised lipoprotein(a) in patients with refractory angina , 2015, Global cardiology science & practice.

[12]  D. Gorog,et al.  Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. , 2015, Journal of the American College of Cardiology.

[13]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[14]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[15]  L. Hemphill,et al.  Lipoprotein apheresis. , 2015, Cardiology clinics.

[16]  N. Minamino,et al.  Proteomic Analysis of Proteins Eliminated by Low‐Density Lipoprotein Apheresis , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[17]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[18]  W. Lehmacher,et al.  Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study , 2013, Circulation.

[19]  G. Thompson,et al.  Lipoprotein(a): the underestimated cardiovascular risk factor , 2013, Heart.

[20]  J. Hodges,et al.  Long-term survival in patients with refractory angina. , 2013, European heart journal.

[21]  T. Mollnes,et al.  LDL Apheresis and Inflammation – Implications for Atherosclerosis , 2012, Scandinavian journal of immunology.

[22]  J. Brittenden,et al.  Prothrombotic Changes in Platelet, Endothelial and Coagulation Function following Hemodialysis , 2011, The International journal of artificial organs.

[23]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[24]  D. Stott,et al.  Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. , 2010, Journal of the American College of Cardiology.

[25]  H. Borberg.  Comparison of different Lp (a) elimination techniques: a retrospective evaluation. , 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[26]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[27]  G. Utermann,et al.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events , 2009, Nature Clinical Practice Cardiovascular Medicine.

[28]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[29]  K. Kensey,et al.  Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. , 2004, The American journal of cardiology.

[30]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[31]  M. Pasic,et al.  The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. , 2002, European heart journal.

[32]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[33]  T. Ortel,et al.  Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. , 1994, Clinical chemistry.

[34]  E. B. Smith.  Fibrin deposition and fibrin degradation products in atherosclerotic plaques. , 1994, Thrombosis research.

[35]  R. Muche,et al.  Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) , 1994, European journal of clinical investigation.

[36]  H. Pelzer,et al.  Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent Assay , 1988, Thrombosis and Haemostasis.

[37]  W. Engel,et al.  The hemostatic imbalance of plasma-exchange transfusion. , 1979, Blood.

[38]  K. Berg.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. , 2009, Acta pathologica et microbiologica Scandinavica.